drugset / Trial / NCT00863278

Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser

NCT00863278

Phase 4 Terminated 20 enrolled Centre Hospitalier Universitaire de Nice
RandomizedParallel-groupSingle-blindTreatment

Summary

Melasma is an acquired disorder of pigmentation that leads to irregular pigmented patches on the face. Treatment is difficult and to date the best treatment option is the combination of hydroquinone, retinoic acid and steroids combined in topical daily application (called Kligman's trio). Q-switched pigmentary lasers are usually ineffective and can induce post inflammatory hyperpigmentation (PIH). Intense pulsed light can sometimes improve melasma but also induce PIH which limit their use. Recently, pulsed dye laser were demonstrated to be effective in treating some pigmentary defects. Associating blanching cream with hydroquinone to prevent PIH after laser or intense pulsed light has been already reported with success. The objective of the study is to compare in a prospective intra individual comparative trial the association of pulsed dye laser plus stabilized Kligman's trio to Kligman's trio alone. The secondary objective was to study the frequency and the intensity of the potential side effects including PIH.

Timeline

Start
2009-03
Primary completion
2010-03
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroquinone Small molecule Topical
Comparator Isotretinoin Other / unclassified Topical